OncoMatch/Clinical Trials/NCT04696029
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Is NCT04696029 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Difluoromethylornithine for medulloblastoma.
Treatment: Difluoromethylornithine — Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: MYC amplification
MYC amplified Group 3
Required: MYCN amplification
MYCN amplified
Required: TP53 mutation
TP53 mutant non-infant (>3 yrs) SHH
Disease stage
Required: Stage IV
Molecular High Risk and Very High Risk definitions include metastatic status; relapsed/refractory cohort included
Prior therapy
Cannot have received: investigational drug
Subjects who are currently receiving another investigational drug are excluded from participation.
Cannot have received: anticancer agents
Subjects who are currently receiving other anticancer agents are not eligible.
Lab requirements
Blood counts
anc ≥750/μl, platelets ≥30 (non-transfused x 7 days)
Kidney function
creatinine clearance or radioisotope gfr ≥ 70 ml/min/1.73 m2 or a serum creatinine based on age/gender
Liver function
ast and alt <10x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arkansas Children's Hospital · Little Rock, Arkansas
- UCSF Benioff Children's Hospital Oakland · Oakland, California
- Rady Children's Hospital · San Diego, California
- Stanford University · Stanford, California
- Connecticut Children's Hospital · Hartford, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify